The FDA's Latest Victim

The FDA just can't seem to approve anything these days. Earlier in the week, the agency delayed Eli Lilly's (NYSE: LLY  ) heart drug prasugrel. Now, Merck (NYSE: MRK  ) says it'll have to wait for a label change to its already-approved human papillomavirus (HPV) vaccine, Gardasil.

Merck said that the FDA has some "issues" with the drugmaker's request to expand the approved age range to include women aged 27 though 45 -- the vaccine is currently approved for females aged nine through 26. The data from a trial in older women looked good, so I'm a little surprised at the agency's move. Since Merck plans to have all the agency's questions answered next month, it's possible that the issues are minor and that it's just another case of the FDA not getting its job done in time.

The drugmaker also said that the FDA wouldn't approve a change to the label stating that the vaccine helps protect patients against other strains that cause cervical cancer. That doesn't seem like a major issue to me; the vaccine already claims to protect against four strains that cover a majority of cervical cancer and genital warts cases, so the additional wording probably wouldn't add much to sales.

Ironically, the FDA's increased scrutiny could be the best thing for Merck. GlaxoSmithKline (NYSE: GSK  ) is still trying to get its HPV vaccine, Cervarix, approved after the FDA rejected it last December. Given the choice of a rigorous FDA that denies or delays its label expansions and Cervarix's approval, versus a lax FDA that lets them both through, I think Merck would pick the rigorous FDA. Clearly, the added sales to older women would be nice, but the competition-free period in the U.S. that Merck is enjoying added nearly $300 million in sales last quarter alone.

Glaxo and Eli Lilly are both Income Investor recommendations. To see how dividend-paying stocks can offer both secure income and the opportunity for growth, take a free look at this newsletter with a 30-day free trial.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 673625, ~/Articles/ArticleHandler.aspx, 10/26/2016 12:04:35 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 2 hours ago Sponsored by:
DOW 18,169.27 -53.76 -0.30%
S&P 500 2,143.16 -8.17 -0.38%
NASD 5,283.40 -26.43 -0.50%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/25/2016 4:00 PM
LLY $77.75 Up +0.18 +0.23%
Eli Lilly and Co. CAPS Rating: ***
GSK $40.32 Down -0.36 -0.88%
GlaxoSmithKline CAPS Rating: ***
MRK $61.95 Up +1.20 +1.98%
Merck and Co. CAPS Rating: ****